Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Screening for prostate cancer: synthesis].

P Mongiat-Artus1, P Teillac

  • 1Service d'urologie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France. pierre.mongiat-artus@sls.aphp.fr

Annales D'Urologie
|May 20, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perioperative results of radical cystectomy after neoadjuvant chemotherapy according to the implementation of ERAS pathway.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2022
Same author

Corrigendum to "French ccAFU guidelines-update 2020-2022: Prostate cancer" [Prog. Urol 30 (12 S) (2020), pp S136-S251].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2021
Same author

[Update on the risk of corticosterone therapy in combination with abiraterone acetate during the COVID-19 pandemic].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2021
Same author

Morbidity and long-term results of subcutaneous pyelovesical bypass in chronic ureteral obstruction.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2021
Same author

[French ccAFU guidelines - update 2020-2022: prostate cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2020
Same author

[French CCAFU guidelines on prostate cancer: hormone-sensitive metastatic prostate cancer-update 2020].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2020
Same journal

Prostate cancer at the 2007 ASCO meeting: an urologist's perspective.

Annales d'urologie·2008
Same journal

[Surgical treatment of ureteropyelic junction stenosis using robotic-assisted laparoscopy].

Annales d'urologie·2008
Same journal

[Robotic-assisted laparoscopy: general principles].

Annales d'urologie·2008
Same journal

[De novo tumours of renal transplants].

Annales d'urologie·2008
Same journal

[Immunosuppression in kidney transplantation].

Annales d'urologie·2008
Same journal

[Surgical complications in kidney transplantation].

Annales d'urologie·2008
See all related articles

Prostate cancer (PCa) screening effectiveness is debated. While reducing mortality, it risks over-diagnosis and over-treatment due to low PSA test specificity, necessitating patient and physician re-education.

Area of Science:

  • Oncology
  • Urology
  • Public Health

Context:

  • Prostate cancer (PCa) screening is controversial, with ongoing trials and existing US practices showing reduced mortality but potential over-diagnosis.
  • The debate stems from the low specificity of Prostate-Specific Antigen (PSA) tests, leading to treatment of insignificant PCa and associated complications.
  • Current screening discussions often conflate diagnostic goals with therapeutic actions, creating a misunderstanding of the screening's true impact.

Purpose:

  • To analyze the ongoing debate surrounding prostate cancer screening effectiveness and its implications.
  • To highlight the issue of over-diagnosis and over-treatment resulting from current screening practices.
  • To propose a shift in focus from disease detection to informed decision-making regarding treatment.

Summary:

Related Experiment Videos

  • Mass screening for prostate cancer (PCa) in the US has decreased mortality but raises concerns about over-diagnosis of insignificant tumors and subsequent over-treatment.
  • The low specificity of PSA testing contributes to this issue, leading to unnecessary complications.
  • The core problem lies not in detecting PCa but in managing the findings, emphasizing the need for patient education and revised treatment decision processes.

Impact:

  • Re-educating patients on PCa and physicians on treatment decisions is crucial before widespread screening implementation.
  • Individual screening, coupled with patient education, is suggested as a more prudent approach pending policy decisions.
  • This approach aims to improve understanding and decision-making, mitigating the risks associated with over-diagnosis and over-treatment in prostate cancer care.